Epistemis

CNS Demyelinating Diseases

Demyelinating CNS Diseases — Expert Level Reference

How it begins

Del oligodendrocito y la arquitectura molecular del nódulo de Ranvier a la placa, el brote y la progresión silente. Esclerosis múltiple, neuromielitis óptica, MOGAD, encefalomielitis aguda diseminada y las desmielinizaciones metabólico-tóxicas e infecciosas, con su biología, inmunopatología, criterios diagnósticos detallados, neuroimagen, líquido cefalorraquídeo, biomarcadores y el arsenal terapéutico moderno…

What it covers

  1. Concept, terminology and classification of demyelinating diseases
  2. · Operational etiopathogenic classification
  3. · An essential historical note
  4. Myelin: cell biology, biochemistry and the architecture of the node of Ranvier
  5. · The oligodendrocyte versus the Schwann cell
  6. · Biochemistry: lipids and proteins of central myelin
  7. · The molecular architecture of the node of Ranvier
  8. · Myelin as trophic support of the axon
  9. Pathophysiology of demyelination, conduction block and remyelination
  10. · From healthy fiber to clinical deficit
  11. · Clinical correlates of altered physiology
  12. · Remyelination: why it exists and why it fails
  13. Multiple sclerosis: epidemiology
  14. · Distribution by age, sex and time
  15. · The latitudinal gradient and migration studies
  16. Etiology and risk factors of multiple sclerosis
  17. · Genetic susceptibility
  18. · Environmental factors
  19. Immunopathology of multiple sclerosis
  20. · The immunological cascade: from outside to inside the CNS
  21. · Lassmann-Lucchinetti patterns
  22. Neuropathology: plaque and gray matter pathology
  23. · Classification of plates according to their activity
  24. · The revolution in gray matter pathology
  25. Clinical manifestations: the topographic syndromes of the outbreak
  26. · Optic neuritis
  27. · Myelitis (partial)
  28. · Brainstem and cranial nerve syndromes
  29. · Cerebellar syndromes
  30. Symptoms throughout the disease: fatigue, cognition, mood and paroxysmal phenomena
  31. · Fatigue
  32. · Cognitive impairment
  33. · Psychiatric symptoms
  34. · Bladder, intestinal and sexual dysfunction
  35. · Pain, spasticity and paroxysmal phenomena
  36. Phenotypes and evolutionary course
  37. · From subclinical risk to progressive forms
  38. · Disability measurement and prognosis
  39. Diagnosis: McDonald's criteria
  40. · Operational definitions
  41. · The contribution of oligoclonal bands (McDonald 2017)
  42. · Diagnostic scenarios according to clinical presentation
  43. Complementary tests: MRI, cerebrospinal fluid, evoked potentials and OCT
  44. · Magnetic resonance: the paraclinical pillar
  45. · Cerebrospinal fluid
  46. · Evoked potentials and optical coherence tomography
  47. · Biomarkers in blood
  48. Differential diagnosis and red flags
  49. · Main imitators (“MS mimics”)
  50. Treatment of acute outbreak
  51. · Corticosteroids at high doses
  52. · Plasmapheresis and rescue options
  53. Disease-modifying therapies (TME/DMT)
  54. · Pharmacological overview
  55. · Screening, monitoring and the threat of PML
  56. Symptomatic treatment and rehabilitation
  57. · Management by symptoms
  58. Special situations: pregnancy, pediatric MS, vaccination and comorbidity
  59. · MS and pregnancy
  60. · Pediatric MS
  61. · Vaccination and immunization
  62. Neuromyelitis optica spectrum disorders (NMOSD)
  63. · Immunopathology
  64. · Cardinal clinical syndromes
  65. · Diagnosis (international criteria 2015)
  66. Anti-MOG antibody disease (MOGAD)
  67. · Clinical phenotypes according to age
  68. Acute disseminated encephalomyelitis (ADEM) and post-infectious demyelination
  69. · Clinical and differential features
  70. Focal demyelinating syndromes and variants of multiple sclerosis
  71. · "Isolated" demyelinating syndromes
  72. · Fulminant and atypical variants of MS
  73. Metabolic, toxic and infectious demyelination
  74. · Osmotic demyelination syndrome (myelinolysis)
  75. · Other non-immune acquired demyelination
  76. Diagnostic integration and demyelinating emergencies
  77. · Mental approximation algorithm
  78. · Comparison of the three major immune-mediated entities
  79. · Demyelinating emergencies that do not allow delay

The complete study guide is in the app

This page summarizes the outline. The full interactive study guide —with high-yield diagrams, clinical tables, and board review cases— can be read inside Epistemis, completely offline and ad-free.

Subject
Neurology
Category
Clinical Specialties
Type
Study Guide
Sections
79
Reviewed
2026-08-02
Download Epistemis